Literature DB >> 19944882

Management of schizophrenia with medical disorders: cardiovascular, pulmonary, and gastrointestinal.

Delmar D Short1, Joanne M Hawley, Maureen F McCarthy.   

Abstract

Medical illnesses are particularly common in patients who have schizophrenia and one of the major tasks for consultation-liaison psychiatrists, and others, is to determine which medications are safest in which co-morbid condition. The authors review the relative risks for various antipsychotics, especially focusing on cardiovascular, pulmonary, and gastrointestinal co-morbid illnesses. The authors further review the atypical antipsychotics' cardiovascular risks, especially for prolonging QT intervals, in trying to avoid the risk for torsades de pointes. The relative risk for anticholinergic actions for these medicines is also reviewed, as this is especially important in the medically ill or elderly. The authors also review the relative safety of antipsychotics in patients who have liver disease and pulmonary disease. Finally, the authors review specific drug interactions that may be problematic when treating the medically ill with atypical antipsychotics.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19944882     DOI: 10.1016/j.psc.2009.09.005

Source DB:  PubMed          Journal:  Psychiatr Clin North Am        ISSN: 0193-953X


  3 in total

1.  Characterization of schizophrenia adverse drug interactions through a network approach and drug classification.

Authors:  Jingchun Sun; Min Zhao; Ayman H Fanous; Zhongming Zhao
Journal:  Biomed Res Int       Date:  2013-09-09       Impact factor: 3.411

2.  Mental health consumers' with medical co-morbidity experience of the transition through tertiary medical services to primary care.

Authors:  Kate Cranwell; Meg Polacsek; Terence V McCann
Journal:  Int J Ment Health Nurs       Date:  2016-01-05       Impact factor: 3.503

3.  Improving mental health service users' with medical co-morbidity transition between tertiary medical hospital and primary care services: a qualitative study.

Authors:  Kate Cranwell; Meg Polacsek; Terence V McCann
Journal:  BMC Health Serv Res       Date:  2016-07-26       Impact factor: 2.655

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.